- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.79 Å
- Oligo State
- homo-dimer
- Ligands
- 4 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.2: 11 residues within 4Å:- Chain A: S.400, R.446, I.449, K.450, C.453, D.461, S.463, N.485, S.487, Y.508, D.510
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:R.446, A:N.513
- Water bridges: A:S.487
NAG-NAG-BMA.5: 11 residues within 4Å:- Chain B: R.446, I.449, K.450, C.453, S.463, L.464, N.485, S.487, Y.508, D.510, N.513
2 PLIP interactions:2 interactions with chain B- Hydrogen bonds: B:R.446, B:N.513
- 12 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.7: 3 residues within 4Å:- Chain A: S.496, N.520, S.522
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:S.522
NAG.8: 3 residues within 4Å:- Chain A: N.630, N.654, L.657
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:N.630
NAG.9: 5 residues within 4Å:- Chain A: L.341, S.342, R.344, P.368, N.369
3 PLIP interactions:3 interactions with chain A- Hydrophobic interactions: A:P.368
- Hydrogen bonds: A:R.344, A:R.344
NAG.10: 4 residues within 4Å:- Chain A: E.358, Q.362, M.365, N.390
4 PLIP interactions:4 interactions with chain A- Hydrogen bonds: A:Q.362, A:Q.366
- Water bridges: A:E.358, A:N.390
NAG.11: 5 residues within 4Å:- Chain A: K.561, K.582, S.583, V.585, N.614
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:N.614
- Water bridges: A:N.614, A:N.614
NAG.12: 4 residues within 4Å:- Chain A: K.37, G.59, Q.61, N.62
2 PLIP interactions:2 interactions with chain A- Hydrophobic interactions: A:Q.61
- Hydrogen bonds: A:N.62
NAG.15: 3 residues within 4Å:- Chain B: S.496, N.520, S.522
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:S.522
NAG.16: 3 residues within 4Å:- Chain B: N.630, N.654, L.657
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:N.630
NAG.17: 5 residues within 4Å:- Chain B: L.341, S.342, R.344, P.368, N.369
3 PLIP interactions:3 interactions with chain B- Hydrophobic interactions: B:P.368
- Hydrogen bonds: B:R.344, B:R.344
NAG.18: 4 residues within 4Å:- Chain B: E.358, Q.362, M.365, N.390
2 PLIP interactions:2 interactions with chain B- Hydrogen bonds: B:Q.366
- Water bridges: B:Q.362
NAG.19: 5 residues within 4Å:- Chain B: K.561, K.582, S.583, V.585, N.614
3 PLIP interactions:3 interactions with chain B- Hydrogen bonds: B:N.614
- Water bridges: B:N.614, B:N.614
NAG.20: 4 residues within 4Å:- Chain B: K.37, G.59, Q.61, N.62
2 PLIP interactions:2 interactions with chain B- Hydrophobic interactions: B:Q.61
- Hydrogen bonds: B:N.62
- 2 x YHG: (3~{S})-~{N}-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4~{H}-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]morpholine-3-carboxamide(Non-covalent)
YHG.13: 19 residues within 4Å:- Chain A: F.235, F.320, Y.322, I.323, K.324, G.325, S.326, G.350, V.352, I.377, F.379, E.401, L.464
- Chain B: F.468, F.469, S.490, A.492, Q.493, R.515
18 PLIP interactions:7 interactions with chain B, 11 interactions with chain A- Hydrophobic interactions: B:F.468, B:F.469, B:F.469, B:A.492, A:F.320, A:Y.322, A:Y.322, A:Y.322, A:V.352, A:V.352, A:I.377
- Hydrogen bonds: B:S.490, B:S.490, B:V.494, A:G.325, A:E.401
- pi-Stacking: A:F.235, A:F.379
YHG.14: 19 residues within 4Å:- Chain A: F.468, F.469, S.490, A.492, Q.493, R.515
- Chain B: F.235, F.320, Y.322, I.323, K.324, G.325, S.326, G.350, V.352, I.377, F.379, E.401, L.464
18 PLIP interactions:8 interactions with chain A, 10 interactions with chain B- Hydrophobic interactions: A:F.468, A:F.469, A:F.469, A:A.492, B:F.320, B:Y.322, B:V.352, B:V.352, B:F.379
- Hydrogen bonds: A:S.490, A:S.490, A:V.494, B:G.325
- Water bridges: A:R.515, B:R.403, B:R.403
- pi-Stacking: B:F.235, B:F.379
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Alper, P. et al., Discovery of the TLR7/8 Antagonist MHV370 for Treatment of Systemic Autoimmune Diseases. Acs Med.Chem.Lett. (2023)
- Release Date
- 2023-08-16
- Peptides
- Toll-like receptor 8: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.79 Å
- Oligo State
- homo-dimer
- Ligands
- 4 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 12 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 2 x YHG: (3~{S})-~{N}-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4~{H}-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]morpholine-3-carboxamide(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Alper, P. et al., Discovery of the TLR7/8 Antagonist MHV370 for Treatment of Systemic Autoimmune Diseases. Acs Med.Chem.Lett. (2023)
- Release Date
- 2023-08-16
- Peptides
- Toll-like receptor 8: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B